Obesity Clinical Trials

• Signed informed consent prior to start the Screening Visit procedures.

• Female and male participants ≥18 years of age at time of consent

• BMI g ≥27.0 kg/m2 at screening.

• HbA1c ≥7 and ≤10% (53-86 mmol/mol) at screening.

• Diagnosis of type 2 diabetes mellitus for ≥ 180 days prior to screening.

• Either treated with diet and exercise alone or on stable (at least 90 days prior to screening) treatment with metformin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, sulfonylurea, and/or DPP4 inhibitor as monotherapy or combination therapy, per approved local label.

• a) Note: Participants treated with sulfonylureas and/or DPP4 inhibitors must discontinue these at least 24 hours prior to initiation of semaglutide.

• Participant has had at least 1 unsuccessful attempt at weight loss by diet and exercise in the opinion of the investigator.

• Women of childbearing potential (WOCBP) meeting the criteria below:

• i) Non-lactating and has a negative pregnancy test at screening and baseline -AND- ii) Uses an acceptable method of contraception as determined by the Investigator or Sub-Investigator for the duration of the study and 30 days following the last dose of study drug

• Participants must, in the opinion of the Investigator, be suitable candidates to receive semaglutide (Wegovy®) as indicated according to the product label.